{
    "clinical_study": {
        "@rank": "1510", 
        "arm_group": [
            {
                "arm_group_label": "Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd", 
                "arm_group_type": "Experimental", 
                "description": "Single administration : 6 days, per oral"
            }, 
            {
                "arm_group_label": "Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd", 
                "arm_group_type": "Experimental", 
                "description": "Single administration : 6 days, per oral"
            }, 
            {
                "arm_group_label": "Concor 5mg 2T and Crestor 20 mg 1Tab, qd", 
                "arm_group_type": "Experimental", 
                "description": "Combination administration : 6 days, per oral"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designated to evaluate the pharmacokinetic interactions of bisoprolol and\n      rosuvastatin in healthy male volunteers."
        }, 
        "brief_title": "Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male volunteers in the age between 20 and 55 years old(inclusive)\n\n          -  Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)\n\n          -  Medically healthy with no clinically significant vital signs (sitting position blood\n             pressure, pulse rate) (90 mmHg \u2264 systolic blood pressure \u2264 150 mmHg, 60 mmHg \u2264\n             diastolic blood pressure \u2264 100 mmHg, 50 beats per minute \u2264 pulse rate \u2264 100 beats per\n             minute)\n\n          -  Available for the entire study period\n\n          -  Understand the requirements of the study and voluntarily consent to participate in\n             the study\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of gastrointestinal diseases which might significantly change\n             ADME(Absorption, Distribution, Metabolism and Excretion) of medicines\n\n          -  History of clinically significant arrhythmic, peripheral vascular,thyroid,\n             bronchospasm, asthma disease\n\n          -  Subjects with anaphylaxis to bisoprolol and/or rosuvastatin\n\n          -  History of drug abuse\n\n          -  History of caffeine, alcohol, smoking abuse\n\n               -  caffeine(coffee,tea,coke) or grapefruit juice > 4cups/day\n\n               -  smoking > 20 cigarettes/day\n\n               -  alcohol > 140g/week\n\n          -  Clinical laboratory test values are outside the accepted normal range\n\n               -  AST(Aspartate Transaminase), ALT(ALanine Transaminase)( > 1.5 times to normal\n                  range\n\n               -  CK(Creatine Kinase) > 1.5 times to normal range\n\n               -  Estimated GFR(Glomerular Filtration Rate) < 60 mL/min\n\n          -  Subjects with whole blood donation within 60days, component blood donation within\n             30days and blood transfusion within 30days prior to study medication dosing\n\n          -  Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925300", 
            "org_study_id": "CJ_BCS_101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd", 
                "intervention_name": "Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd", 
                "intervention_name": "Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Concor 5mg 2T and Crestor 20 mg 1Tab, qd", 
                "intervention_name": "Concor 5mg 2T and Crestor 20 mg 1Tab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bisoprolol", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "Safety", 
            "Tolerability"
        ], 
        "lastchanged_date": "August 18, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Bisoprolol and Rosuvastatin in Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Samsung Medical Conter", 
            "last_name": "Jae-wook Ko, phD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Administration of Investigational Product : 6 days/period(total 3 period)", 
            "measure": "Assessment of the drug-drug interactions of bisoprolol and rosuvastatin: Cmax,ss(Maximum steady-state plasma drug concentration during a dosage interval  ), AUC\u03c4(Area Under the Curve)", 
            "safety_issue": "No", 
            "time_frame": "6 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Administration of Investigational Product : 6 days/period(total 3 period)", 
            "measure": "Assessment of the bisoprolol and rosuvastatin:tmax,ss(Time to reach Cmax,ss), t1/2, Cmin,ss(Minimum steady-state plasma drug concentration during a dosage interval  ), CL/Fss(Oral Clearance), Vd/Fss(Apparent Volume of Distribution)", 
            "safety_issue": "No", 
            "time_frame": "6 days"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}